Troubled drug development company Immune Pharmaceuticals plans to focus on monetizing non-core assets in 2015, including selling or licensing neuropathic pain drug AmiKet.

The Cambridge, Massachusetts-based pharmaceutical developer experienced a year of transition in 2014, according to a Jan. 6 letter to shareholders. Immune was listed on the Nasdaq, raised more than $20 million in equity, reduced past liabilities and strengthened its cash position, reports CEO Daniel Teper  in the letter, which was filed with the U.S. Securities and Exchange Commission.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.